Onsite Women’s Health launches AI-enabled mammography programme to surface cardiovascular risk
Designed to identify potential cardiovascular risk during routine screening mammograms.
Onsite Women’s Health has launched a new AI-enabled clinical programme designed to identify potential cardiovascular risk during routine screening mammograms.
The programme, called Mammo with heart, uses FDA-cleared artificial intelligence from CureMetrix to detect breast arterial calcifications (BAC) — a finding associated with cardiovascular disease — during standard 3D mammography exams.
Mammo with heart is currently available at Intermountain Medical Clinic, an Onsite-affiliated practice, with plans to expand to additional markets across the company’s national network this year.
Cardiovascular disease remains the leading cause of death for women, yet risk is frequently under-recognised until later stages. Preventive pathways are often fragmented, with heart health, breast health and primary care operating in parallel rather than in concert.
Breast arterial calcifications are present in an estimated 12% to 42.5% of screening mammograms, yet fewer than 5% of these incidental findings are typically reported. Rather than asking women to undergo more tests, by integrating CureMetrix’s cmAngio® software directly into existing mammography workflows, the programme enables clinicians to surface BAC findings without additional appointments, procedures or radiation exposure.
“We’re thrilled to partner with CureMetrix to explore new ways AI can expand the value of traditional mammography,” said Jillian Wright, chief executive officer at Onsite Women’s Health.
“This partnership allows us to extract more insight from every mammogram — not only to detect cancer, but to inform broader aspects of women’s health, including cardiovascular risk.”
Onsite Women’s Health provides in-office breast health and imaging services across more than 175 practices in 28 U.S. states and is projected to perform over 600,000 breast exams in 2026. The company says the addition of Mammo with heart supports its goal of improving early detection, patient compliance and preventive care outcomes nationwide.
The launch coincides with American Heart Month, highlighting the growing focus on cardiovascular disease within preventive care settings.
Onsite is one of a number of companies pushing mammograms beyond cancer detection. Genexia Health is developing a proprietary AI to assess coronary artery disease risk directly from mammogram data, aiming to generate predictive scores beyond incidental calcification signals.